Chugai in co-development accord for obinutuzumab with Nippon Shinyaku The Pharma Letter GA101 is a glycoengineered type II anti-CD20 monoclonal antibody created by GlycArt AG and is a compound that selectively targets the CD20 protein on B-cells, the same as rituximab (recombinant) which is recommended as a treatment of non-Hodgkin's ... |
